Fellow Health, a pioneering healthtech startup focused on unlocking male fertility insights through semen diagnostics, has raised $24 million in Series B funding. The round was led by 5AM Ventures and The Forest Road Company, and marks a bold move toward reshaping how fertility is diagnosed, understood, and optimized through clinical-grade mail-in testing.

Founded by Brian Hogan, Fellow Health has been pushing the boundaries of what modern diagnostics can achieve, particularly in male reproductive health space historically underfunded, underserved, and even stigmatized. With the latest infusion of capital, the company is doubling down on its mission to make semen analysis more accessible, accurate, and clinically actionable for patients and providers alike.

A New Era of At-Home Fertility Testing

Fellow’s platform offers peer-reviewed, lab-validated semen analysis through a convenient at-home testing model. Unlike traditional fertility assessments that often require in-person visits to specialized clinics, Fellow’s solution brings precision diagnostics directly to the user's doorstep. The samples are then processed in CLIA-certified labs, providing results that adhere to strict clinical standards.

This combination of accessibility and scientific rigor is what sets Fellow apart. The company bridges the gap between patient convenience and provider-grade insight, a balance that many telehealth and diagnostics startups struggle to achieve.

Addressing an Underserved Market

The broader fertility market has exploded in recent years, but men’s health remains comparatively overlooked. Male factors contribute to nearly 50% of infertility cases, yet most solutions focus primarily on women. Fellow Health challenges this asymmetry by placing male fertility on the center stage - not only to improve conception outcomes, but also to highlight male reproductive health as a vital piece of the clinical puzzle.

The company also takes a nuanced approach to data interpretation. Rather than offering a binary "normal/abnormal" result, Fellow provides a detailed report covering metrics like sperm count, motility, morphology, and volume - giving users a more informed foundation for next steps, whether that involves medical consultation or lifestyle changes.

The Invisible Market Opportunity

Here’s where the story gets especially valuable for other startup founders: Fellow Health didn’t just build a product - it saw what others couldn’t. In a healthcare ecosystem saturated with solutions for female fertility, the company spotted a neglected corner of a massive market. It leaned into an uncomfortable but medically essential topic and created infrastructure where there was none.

Fellow’s growth is not just about semen analysis. It’s about recognizing that many healthcare categories still operate under outdated cultural assumptions. Just as early telemedicine companies saw opportunity in eroding the stigma around mental health, Fellow recognized that men needed a discreet, judgment-free avenue to better understand their fertility. And it built precisely that.

Fellow’s evolution reveals a lesson all startup leaders can learn from: the greatest opportunity often lies in rethinking what your customers assume is fixed. Many companies view sensitive health diagnostics as immovable, clinic-bound procedures. But Fellow asked, what if diagnostics - especially those that are private or stigmatized - could thrive outside the clinic? This allowed them to reframe the entire model, turning a historically awkward in-office experience into a user-first digital journey. That shift transforms healthcare from reactionary to proactive. Founders across all sectors should ask themselves: What outdated assumptions are your users quietly tolerating - and how can you rewrite that experience from scratch?

Backed by Science and Strategy

What also makes Fellow stand out is its deep commitment to scientific validation. The company’s internal lab processes are guided by and benchmarked against WHO standards, ensuring clinical reliability. As it expands, Fellow plans to introduce new layers of biomarker tracking, longitudinal data capture, and predictive diagnostics.

The new funding will be directed toward expanding lab capacity, investing in new R&D, and growing its provider-facing offerings. By integrating its platform with clinical networks and electronic health records (EHRs), Fellow aims to serve as more than just a diagnostics company - it wants to become the first node in the male reproductive health journey.

What’s Next for Fellow Health?

With $24 million in fresh capital, the company is expected to scale its direct-to-consumer reach, enhance its enterprise integrations, and further invest in patient education tools. As the lines blur between diagnostics and wellness, Fellow is positioning itself to become the go-to resource for men who want to proactively manage their fertility, not just reactively address it.

By removing barriers to testing, destigmatizing male reproductive health, and combining user-friendly technology with top-tier medical science, Fellow is doing more than growing a company - it’s creating a new category.